Linike Medical Group Ltd
LNMG · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 10.89 | -2.00 | 0.00 | 127.96 |
| FCF Yield | -0.29% | -0.07% | -0.00% | -0.01% |
| EV / EBITDA | -1,872.46 | 3,011.33 | -45,551.80 | -8,532.49 |
| Quality | ||||
| ROIC | -0.46% | 1.90% | 551.44% | 751.19% |
| Gross Margin | 99.58% | 99.27% | 0.00% | 0.00% |
| Cash Conversion Ratio | 3.13 | -2.28 | 0.29 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 57.05% | -11,994.65% | 13.02% | -5.70% |
| Safety | ||||
| Net Debt / EBITDA | -92.20 | 15.43 | -0.94 | -1.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.01 | 0.01 | 0.00 | 0.00 |
| Cash Conversion Cycle | 37,776.23 | 21,500.75 | 0.00 | 0.00 |